RMC No. 42-2023 confirms FDA-endorsed updates to VAT-exempt medicines and applies exemption from FDA publication of the updated list.
Pharmacies, hospitals, clinics, drug distributors, importers, and accounting teams dealing with medicines for cancer, diabetes, kidney disease, mental illness, tuberculosis, high cholesterol, and hypertension should immediately verify whether their products are covered by the FDA-endorsed updates to the List of VAT-Exempt Products. RMC No. 42-2023 matters because VAT exemption for covered medicines and medical devices under the CREATE Act takes effect on the date the Food and Drug Administration publishes the relevant updates to the list, not merely when a taxpayer later discovers or applies the circular.
What RMC No. 42-2023 Changed
RMC No. 42-2023 publishes the full text of the February 21, 2023 letter from the Food and Drug Administration of the Department of Health endorsing updates to the List of VAT-Exempt Products under Republic Act No. 10963, also known as the TRAIN Law, and Republic Act No. 11534, also known as the CREATE Act.
The practical effect is that the BIR has formally circulated the FDA endorsement for inclusion of certain medicines in the published list of VAT-exempt medicines. The circular identifies the covered therapeutic areas as cancer, diabetes, kidney disease, mental illness, and tuberculosis. It also refers to corrections for medicines for high cholesterol and hypertension in the published list of VAT-exempt medicines under the CREATE Act.
For businesses, the key issue is classification. A medicine that falls within a covered disease category is not automatically exempt merely because it is used by a patient with that condition. The product must be part of the FDA-endorsed update to the official VAT-exempt products list, or must be covered by the correction referred to in the circular. Tax, accounting, sales, and billing teams should therefore work from the official FDA-published list and not from general product descriptions alone.
Who Is Most Affected
RMC No. 42-2023 is most relevant to pharmaceutical companies, medicine importers, drug distributors, hospitals, clinics, pharmacies, health maintenance organizations, medical procurement teams, and businesses purchasing large volumes of covered medicines for employee or patient use. It is also relevant to accountants and tax managers reviewing VAT treatment in invoices, official receipts, purchase orders, inventory systems, and enterprise resource planning platforms.
Pharmacies and drug distributors are directly affected because the VAT treatment of covered products must be reflected at the point of sale. Hospitals and clinics are affected because medicines billed to patients may involve mixed VAT treatment depending on whether the medicine is included in the FDA-updated list. Corporate accounting teams are affected because input tax claims, expense booking, and tax reporting can be distorted if VAT-exempt medicines are treated as VATable, or if non-covered medicines are incorrectly treated as exempt.
The circular is also important for businesses searching for terms such as VAT-exempt medicines Philippines, FDA list VAT-exempt medicines, CREATE Act medicines VAT exemption, BIR RMC 42-2023 VAT-exempt products, and VAT exemption for cancer diabetes kidney disease medicines. These are the practical search phrases accountants and CFOs will likely use when reconciling supplier invoices and reviewing pharmaceutical purchases.
Key Compliance Rule and Effective Date
The most important compliance rule in RMC No. 42-2023 is the effective date rule. The circular reiterates the clarification under Q&A No. 1 of RMC No. 99-2021: the effectivity of the VAT exemption of covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the relevant list.
This means that accounting teams should not treat the BIR circular date alone as the operational trigger without checking the FDA publication date applicable to the listed products. The BIR circular was dated April 4, 2023, while the FDA endorsement letter referred to in the circular was dated February 21, 2023. The operative rule stated in the circular, however, is that the VAT exemption applies from the date of publication by the FDA of the updates to the list.
Businesses should therefore identify the FDA publication date for the relevant update and apply the VAT exemption prospectively based on that publication date. If sales, purchases, or billings of covered medicines occurred around the transition period, the tax team should review whether VAT was correctly charged, excluded, or adjusted based on the proper effectivity date.
Covered Product Areas Identified in the Circular
RMC No. 42-2023 identifies the FDA-endorsed update as involving certain medicines for cancer, diabetes, kidney disease, mental illness, and tuberculosis. It also refers to corrections for medicines for high cholesterol and hypertension in the published List of VAT-Exempt Medicines under the CREATE Act.
The circular does not operate as a broad exemption for every medicine connected with these illnesses. Instead, it points taxpayers to the FDA-endorsed updates and corrections to the published list. The safe approach for businesses is to confirm the exact product, generic name, brand, dosage form, and other identifying details against the FDA-published list before changing VAT treatment in invoices or accounting systems.
This is particularly important for companies carrying multiple variants of the same medicine. A product line may include different strengths, dosage forms, package sizes, or product registrations. Tax teams should avoid assuming that all variants are VAT-exempt unless the official list supports that treatment.
Penalties and Tax Risks for Non-Compliance
RMC No. 42-2023 does not state a special penalty unique to this circular. However, incorrect VAT treatment may still create ordinary tax compliance risks. If a seller charges VAT on a product that should be VAT-exempt, it may create customer disputes, pricing issues, and tax reporting complications. If a seller fails to charge VAT on a product that is not covered by the FDA-published list, the business may face exposure during BIR audit for deficiency VAT and related consequences under the Tax Code and applicable regulations.
For buyers, the risk is also practical. A business should not claim input VAT from a purchase that is properly VAT-exempt. If a supplier incorrectly treats a covered medicine as VATable, the buyerβs books may reflect input VAT that should not have been claimed. Conversely, if a supplier incorrectly treats a non-covered product as exempt, the buyer may later face pricing adjustments or documentation issues.
Practical Steps for Businesses
First, identify all medicines in inventory or procurement channels that relate to cancer, diabetes, kidney disease, mental illness, tuberculosis, high cholesterol, and hypertension. Second, compare those products against the FDA-published update to the VAT-exempt products list. Third, confirm the FDA publication date for the update because RMC No. 42-2023 states that the exemption takes effect on that date of publication by the FDA.
Fourth, update billing, point-of-sale, procurement, and ERP tax codes only for products confirmed to be on the official list. Fifth, review invoices issued or received around the FDA publication date to determine whether corrections, credit memos, debit memos, or internal tax adjustments are required. Sixth, retain documentation showing why the product was treated as VAT-exempt, including the applicable FDA-published list entry and internal approval of the tax code change.
Finally, businesses should train sales, pharmacy, procurement, and accounting personnel not to apply VAT exemption based only on disease category. The correct question is not merely whether the medicine is for cancer, diabetes, kidney disease, mental illness, tuberculosis, high cholesterol, or hypertension. The correct question is whether the specific product is included in the FDA-published VAT-exempt list or covered by the relevant correction.
How Ablola, Saribong & Gueco Can Help
RMC No. 42-2023 is a focused but important reminder that VAT treatment for medicines depends on official FDA publication and precise product identification. For companies dealing with high-volume medicine purchases, hospital billing, pharmacy sales, pharmaceutical distribution, or BIR audit exposure, a small classification error can affect thousands of transactions.
Ablola, Saribong & Gueco assists businesses with BIR compliance, VAT classification, tax audit defense, invoice review, pharmaceutical and healthcare regulatory coordination, and tax risk management. If your company needs help reviewing VAT-exempt medicines, correcting billing practices, or preparing for a BIR examination involving VAT-exempt products under the TRAIN Law and CREATE Act, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.